Concepedia

HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

Angelo Di Leo, Stephen Chan, Marianne Paesmans, Kay Friedrichs, Tamás Pintér, V. Cocquyt, Elizabeth Murray, I. Bodrogi, Euan Walpole, Bernard Lespérance,

Breast Cancer Research and Treatment · 2004 · 138 citations · 32 references

DOI

Concepts

References

32

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Thérese Sørlie, Charles M. Perou, Robert Tibshirani et al. · Proceedings of the National Academy of Sciences · 2001 · 10.9K citations · Full text

, , +16

Reporting results of cancer treatment

A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations

, , +16

<i>p53</i> Status and the Efficacy of Cancer Therapy in Vivo

Scott W. Lowe, Stephan Bodis, Andrea I. McClatchey et al. · Science · 1994 · 1.5K citations

, , +17

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

P M O'Connor, Joany Jackman, I Bae et al. · PubMed · 1997 · 882 citations

, , +15

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

Turid Aas, Anne‐Lise Børresen, Stephanie Geisler et al. · Nature Medicine · 1996 · 742 citations

, , +14